142 related articles for article (PubMed ID: 36610599)
1. Previously independent patients with mild-symptomatic COVID-19 are at high risk of developing cognitive impairment but not depression or anxiety.
Gamberini G; Masuccio FG; Cerrato M; Strazzacappa M; Ferraro D; Solaro C
J Affect Disord; 2023 Mar; 324():645-651. PubMed ID: 36610599
[TBL] [Abstract][Full Text] [Related]
2. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
[TBL] [Abstract][Full Text] [Related]
3. Norwegian Coronavirus Disease 2019 (NO COVID-19) Pragmatic Open label Study to assess early use of hydroxychloroquine sulphate in moderately severe hospitalised patients with coronavirus disease 2019: A structured summary of a study protocol for a randomised controlled trial.
Lyngbakken MN; Berdal JE; Eskesen A; Kvale D; Olsen IC; Rangberg A; Jonassen CM; Omland T; Røsjø H; Dalgard O
Trials; 2020 Jun; 21(1):485. PubMed ID: 32503662
[TBL] [Abstract][Full Text] [Related]
4. Demographic and social determinants of cognitive dysfunction following hospitalization for COVID-19.
Valdes E; Fuchs B; Morrison C; Charvet L; Lewis A; Thawani S; Balcer L; Galetta SL; Wisniewski T; Frontera JA
J Neurol Sci; 2022 Jul; 438():120146. PubMed ID: 35031121
[TBL] [Abstract][Full Text] [Related]
5. Testing the efficacy and safety of BIO101, for the prevention of respiratory deterioration, in patients with COVID-19 pneumonia (COVA study): a structured summary of a study protocol for a randomised controlled trial.
Dioh W; Chabane M; Tourette C; Azbekyan A; Morelot-Panzini C; Hajjar LA; Lins M; Nair GB; Whitehouse T; Mariani J; Latil M; Camelo S; Lafont R; Dilda PJ; Veillet S; Agus S
Trials; 2021 Jan; 22(1):42. PubMed ID: 33430924
[TBL] [Abstract][Full Text] [Related]
6. Cognitive decline among individuals with history of mild symptomatic SARS-CoV-2 infection: A longitudinal prospective study nested to a population cohort.
Del Brutto OH; Wu S; Mera RM; Costa AF; Recalde BY; Issa NP
Eur J Neurol; 2021 Oct; 28(10):3245-3253. PubMed ID: 33576150
[TBL] [Abstract][Full Text] [Related]
7. COVID-19 cognitive deficits after respiratory assistance in the subacute phase: A COVID-rehabilitation unit experience.
Alemanno F; Houdayer E; Parma A; Spina A; Del Forno A; Scatolini A; Angelone S; Brugliera L; Tettamanti A; Beretta L; Iannaccone S
PLoS One; 2021; 16(2):e0246590. PubMed ID: 33556127
[TBL] [Abstract][Full Text] [Related]
8. Subcutaneous Sarilumab in hospitalised patients with moderate-severe COVID-19 infection compared to the standard of care (SARCOVID): a structured summary of a study protocol for a randomised controlled trial.
Garcia-Vicuña R; Abad-Santos F; González-Alvaro I; Ramos-Lima F; Sanz JS
Trials; 2020 Sep; 21(1):772. PubMed ID: 32907638
[TBL] [Abstract][Full Text] [Related]
9. Hydroxychloroquine in the treatment of adult patients with Covid-19 infection in a primary care setting (LIBERTY): A structured summary of a study protocol for a randomised controlled trial.
Vainio PJ; Hietasalo P; Koivisto AL; Kääriäinen S; Turunen J; Virtala M; Vuorinen J; Scheinin M
Trials; 2021 Jan; 22(1):44. PubMed ID: 33430933
[TBL] [Abstract][Full Text] [Related]
10. Critical role of acute hypoxemia on the cognitive impairment after severe COVID-19 pneumonia: a multivariate causality model analysis.
García-Grimshaw M; Chirino-Pérez A; Flores-Silva FD; Valdés-Ferrer SI; Vargas-Martínez MLÁ; Jiménez-Ávila AI; Chávez-Martínez OA; Ramos-Galicia EM; Marché-Fernández OA; Ramírez-Carrillo MF; Grajeda-González SL; Ramírez-Jiménez ME; Chávez-Manzanera EA; Tusié-Luna MT; Ochoa-Guzmán A; Cantú-Brito C; Fernandez-Ruiz J; Chiquete E
Neurol Sci; 2022 Apr; 43(4):2217-2229. PubMed ID: 35022935
[TBL] [Abstract][Full Text] [Related]
11. Intensive care for seriously ill patients affected by novel coronavirus sars - CoV - 2: Experience of the Crema Hospital, Italy.
Zuccon W; Comassi P; Adriani L; Bergamaschini G; Bertin E; Borromeo R; Corti S; De Petri F; Dolci F; Galmozzi A; Gigliotti A; Gualdoni L; Guerra C; Khosthiova A; Leati G; Lupi G; Moscato P; Perotti V; Piantelli M; Ruini A; Sportelli S; Susca M; Troiano C; Benelli G; Buscarini E; Canetta C; Merli G; Scartabellati A; Melilli B S C G; Sfogliarini R; Pellegatta G; Viganò G
Am J Emerg Med; 2021 Jul; 45():156-161. PubMed ID: 33046317
[TBL] [Abstract][Full Text] [Related]
12. A Phase 3 Open-label, Randomized, Controlled Study to Evaluate the Efficacy and Safety of Intravenously Administered Ravulizumab Compared with Best Supportive Care in Patients with COVID-19 Severe Pneumonia, Acute Lung Injury, or Acute Respiratory Distress Syndrome: A structured summary of a study protocol for a randomised controlled trial.
Smith K; Pace A; Ortiz S; Kazani S; Rottinghaus S
Trials; 2020 Jul; 21(1):639. PubMed ID: 32660611
[TBL] [Abstract][Full Text] [Related]
13. Screening for cognitive sequelae of SARS-CoV-2 infection: a comparison between the Mini-Mental State Examination (MMSE) and the Montreal Cognitive Assessment (MoCA).
Aiello EN; Fiabane E; Manera MR; Radici A; Grossi F; Ottonello M; Pain D; Pistarini C
Neurol Sci; 2022 Jan; 43(1):81-84. PubMed ID: 34668124
[TBL] [Abstract][Full Text] [Related]
14. Premorbid vulnerability and disease severity impact on Long-COVID cognitive impairment.
Cristillo V; Pilotto A; Cotti Piccinelli S; Bonzi G; Canale A; Gipponi S; Bezzi M; Leonardi M; Padovani A;
Aging Clin Exp Res; 2022 Jan; 34(1):257-260. PubMed ID: 35014002
[TBL] [Abstract][Full Text] [Related]
15. Dissipating the fog: Cognitive trajectories and risk factors 1 year after COVID-19 hospitalization.
Gonçalves NG; Aliberti MJR; Bertola L; Avelino-Silva T; Dias MB; Apolinario D; Busatto G; Forlenza O; Nitrini R; Brucki SMD; Brunoni AR; Vidal KSM; Jacob-Filho W; Suemoto CK;
Alzheimers Dement; 2023 Sep; 19(9):3771-3782. PubMed ID: 36861807
[TBL] [Abstract][Full Text] [Related]
16. Hyposmia Is Associated with Reduced Cognitive Function in COVID-19: First Preliminary Results.
Pirker-Kees A; Platho-Elwischger K; Hafner S; Redlich K; Baumgartner C
Dement Geriatr Cogn Disord; 2021; 50(1):68-73. PubMed ID: 33853062
[TBL] [Abstract][Full Text] [Related]
17. The SARS-CoV-2 Ivermectin Navarra-ISGlobal Trial (SAINT) to Evaluate the Potential of Ivermectin to Reduce COVID-19 Transmission in low risk, non-severe COVID-19 patients in the first 48 hours after symptoms onset: A structured summary of a study protocol for a randomized control pilot trial.
Chaccour C; Ruiz-Castillo P; Richardson MA; Moncunill G; Casellas A; Carmona-Torre F; Giráldez M; Mota JS; Yuste JR; Azanza JR; Fernández M; Reina G; Dobaño C; Brew J; Sadaba B; Hammann F; Rabinovich R
Trials; 2020 Jun; 21(1):498. PubMed ID: 32513289
[TBL] [Abstract][Full Text] [Related]
18. Reconvalescent plasma/camostat mesylate in early SARS-CoV-2 Q-PCR positive high-risk individuals (RES-Q-HR): a structured summary of a study protocol for a randomized controlled trial.
Keitel V; Jensen B; Feldt T; Fischer JC; Bode JG; Matuschek C; Bölke E; Budach W; Plettenberg C; Scheckenbach K; Kindgen-Milles D; Timm J; Müller L; Kolbe H; Stöhr A; Calles C; Hippe A; Verde P; Spinner CD; Schneider J; Wolf T; Kern WV; Nattermann J; Zoufaly A; Ohmann C; Luedde T;
Trials; 2021 May; 22(1):343. PubMed ID: 34001215
[TBL] [Abstract][Full Text] [Related]
19. Randomized clinical trial to compare the efficacy of ivermectin versus placebo to negativize nasopharyngeal PCR in patients with early COVID-19 in Peru (SAINT-Peru): a structured summary of a study protocol for randomized controlled trial.
Garcia PJ; Mundaca H; Ugarte-Gil C; Leon P; Malaga G; Chaccour C; Carcamo CP
Trials; 2021 Apr; 22(1):262. PubMed ID: 33836826
[TBL] [Abstract][Full Text] [Related]
20. Myoclonus status revealing COVID 19 infection.
Ben Mohamed D; Zouari R; Ketata J; Nabli F; Blel S; Ben Sassi S
Seizure; 2023 Jan; 104():12-14. PubMed ID: 36446232
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
